We cordially invite you to our seminar on Brexit & Implications for the Pharma Sector, taking place on Thursday, 21 March 2019, from 1 pm till 3.30 pm.
On 29 March 2019, the UK will leave the EU. Whether there will be a transitional period until 31 December 2020 remains uncertain despite the desire for a deal. In any event, the general direction of travel continues towards the EU and the UK becoming separate jurisdictions for all regulatory issues, such as marketing authorisations for medicines, pharmacovigilance, clinical trials and medical devices.
From a continental based perspective, separate marketing authorisations will be required to access that market. Clinical trials for EU and UK marketing authorisations will be subject to separate regimes. For pharmacovigilance, qualified persons will need to be appointed in both jurisdictions, as will authorised representatives for medical devices. Just in time delivery of active ingredients, medicinal products and medical devices across the new UK-EU border will require adapted logistics.
Find out how to best prepare your business for the post-Brexit environment, particularly for the scenario of a No Deal.
Our international experts will guide you through:
- Possible Brexit scenarios
- Implications for regulatory issues, IP, logistics, contracts and litigation
- A Brexit checklist
- Key DP issues
The seminar will be held in English, and admission is free.
13:00 - 13:30 Registration and lunch
13:30 - 15:30 Lunch
We look forward to hosting you!
Please send your registration to [email protected] before 19 March 2019 at 12 pm.